Dr. Bianca B. Ferrari
Claim this profileRegional Cancer Center-Lee Memorial Health System
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
3 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials Bianca B. Ferrari is currently running
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
Ramucirumab + Chemotherapy
for Small Bowel Cancer
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to tumor which may interfere with tumor cell growth and expansion. Drugs used in chemotherapy, such as paclitaxel, leucovorin calcium, fluorouracil, and irinotecan hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ramucirumab plus paclitaxel or FOLFIRI, may be helpful in treating advanced or refractory small bowel cancers and may help patients live longer.
Recruiting1 award Phase 217 criteria
More about Bianca B. Ferrari
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Bianca B. Ferrari has experience with
- Lenalidomide
- Daratumumab/rHuPH20
- Ramucirumab
- Irinotecan Hydrochloride
- Fluorouracil
- Irinotecan
Breakdown of trials Bianca B. Ferrari has run
Multiple Myeloma
Plasma Cell Neoplasms
Small Intestinal Adenocarcinoma
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bianca B. Ferrari specialize in?
Bianca B. Ferrari focuses on Multiple Myeloma and Plasma Cell Neoplasms. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Bianca B. Ferrari currently recruiting for clinical trials?
Yes, Bianca B. Ferrari is currently recruiting for 2 clinical trials in Fort Myers Florida. If you're interested in participating, you should apply.
Are there any treatments that Bianca B. Ferrari has studied deeply?
Yes, Bianca B. Ferrari has studied treatments such as Lenalidomide, Daratumumab/rHuPH20, Ramucirumab.
What is the best way to schedule an appointment with Bianca B. Ferrari?
Apply for one of the trials that Bianca B. Ferrari is conducting.
What is the office address of Bianca B. Ferrari?
The office of Bianca B. Ferrari is located at: Regional Cancer Center-Lee Memorial Health System, Fort Myers, Florida 33905 United States. This is the address for their practice at the Regional Cancer Center-Lee Memorial Health System.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.